BLASUBCUTANEOUSSYRINGE
Approved
Mar 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
REBIF (interferon beta-1a) by Biogen is mechanism(s) by which rebif (interferon beta-1a) exerts its therapeutic effects in patients with multiple sclerosis is unknown. First approved in 2002.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REBIF (interferon beta-1a) is a recombinant interferon beta therapeutic administered subcutaneously for multiple sclerosis. The exact mechanism of action remains unknown, though it modulates immune function to reduce disease progression. It represents a foundational immunomodulatory approach in MS treatment.
$0.131BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with ~12K annual claims signals transition from growth maintenance to defense, requiring smaller but highly specialized teams focused on patient retention.
Mechanism of Action
mechanism(s) by which REBIF (interferon beta-1a) exerts its therapeutic effects in patients with multiple sclerosis is unknown.
Pharmacologic Class:
Interferon beta
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
Started Apr 2021
470 enrolled
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Started Oct 2019
152 enrolled
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
Started Mar 2019
11 enrolled
Multiple Sclerosis, Relapsing-Remitting
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
Started Dec 2017
168 enrolled
Relapsing Remitting Multiple Sclerosis (RRMS)
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)
Started Nov 2017
40 enrolled
BioequivalenceHealthy
Worked on REBIF at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.